The more recent EZH2 inhibitor GSK126 was also highly selective for mutant EZH2 lymphoma cells in vivo and led to increased activation of known EZH2 target genes, such as TXNIP and TNFRSF21 (McCabe et al., 2012b). The gene discussed is EZH2; the disease is lymphoma.